PL4028017T3 - Pochodne 1,4-dihydrobenzo[d]pirazolo[3,4-f][1,3]diazepiny i powiązane związki jak modulatory kinazy lrrk2, nuak1 i/lub tyk2 do leczenia np. chorób autoimmunologicznych - Google Patents
Pochodne 1,4-dihydrobenzo[d]pirazolo[3,4-f][1,3]diazepiny i powiązane związki jak modulatory kinazy lrrk2, nuak1 i/lub tyk2 do leczenia np. chorób autoimmunologicznychInfo
- Publication number
- PL4028017T3 PL4028017T3 PL20788868.6T PL20788868T PL4028017T3 PL 4028017 T3 PL4028017 T3 PL 4028017T3 PL 20788868 T PL20788868 T PL 20788868T PL 4028017 T3 PL4028017 T3 PL 4028017T3
- Authority
- PL
- Poland
- Prior art keywords
- nuak1
- diazepines
- lrrk2
- dihydrobenzo
- pyrazolo
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 title 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 title 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 title 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 title 1
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 title 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 150000004908 diazepines Chemical class 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899908P | 2019-09-13 | 2019-09-13 | |
| PCT/IB2020/000730 WO2021048620A1 (en) | 2019-09-13 | 2020-09-11 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4028017T3 true PL4028017T3 (pl) | 2024-03-18 |
Family
ID=72801756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20788868.6T PL4028017T3 (pl) | 2019-09-13 | 2020-09-11 | Pochodne 1,4-dihydrobenzo[d]pirazolo[3,4-f][1,3]diazepiny i powiązane związki jak modulatory kinazy lrrk2, nuak1 i/lub tyk2 do leczenia np. chorób autoimmunologicznych |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220380374A1 (pl) |
| EP (2) | EP4327884A3 (pl) |
| JP (2) | JP7796007B2 (pl) |
| KR (1) | KR20220062038A (pl) |
| CN (2) | CN114793435B (pl) |
| AU (1) | AU2020344216A1 (pl) |
| CA (1) | CA3154123A1 (pl) |
| DK (1) | DK4028017T3 (pl) |
| ES (1) | ES2969088T3 (pl) |
| FI (1) | FI4028017T3 (pl) |
| HU (1) | HUE065093T2 (pl) |
| IL (1) | IL291335A (pl) |
| PL (1) | PL4028017T3 (pl) |
| PT (1) | PT4028017T (pl) |
| RS (1) | RS65045B1 (pl) |
| SI (1) | SI4028017T1 (pl) |
| WO (1) | WO2021048620A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220062567A (ko) * | 2019-09-13 | 2022-05-17 | 오리제니스 게엠베하 | 예를 들어 자가면역 질환의 치료를 위한 lrrk2, nuak1 및/또는 tyk2 키나제 조정제로서의 1,4-디히드로벤조[d]피라졸로[3,4-f][1,3]디아제핀 유도체 및 관련 화합물 |
| KR20220062038A (ko) * | 2019-09-13 | 2022-05-13 | 오리제니스 게엠베하 | 예를 들어 자가면역 질환의 치료를 위한 lrrk2, nuak1 및/또는 tyk2 키나제 조정제로서의 1,4-디히드로벤조[d]피라졸로[3,4-f][1,3]디아제핀 유도체 및 관련 화합물 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| JP2025539799A (ja) * | 2022-11-18 | 2025-12-09 | ニューロン２３， インコーポレイテッド | Ｌｒｒｋ２阻害剤およびその使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5802872B2 (ja) * | 2008-09-23 | 2015-11-04 | ザ ジョンズ ホプキンズ ユニヴァーシティー | 縮合ジイミダゾジアゼピン化合物並びにその使用及び製造方法 |
| TWI557121B (zh) * | 2011-04-21 | 2016-11-11 | 原真股份有限公司 | 新穎激酶抑制劑 |
| RU2722149C1 (ru) * | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| KR20220062567A (ko) * | 2019-09-13 | 2022-05-17 | 오리제니스 게엠베하 | 예를 들어 자가면역 질환의 치료를 위한 lrrk2, nuak1 및/또는 tyk2 키나제 조정제로서의 1,4-디히드로벤조[d]피라졸로[3,4-f][1,3]디아제핀 유도체 및 관련 화합물 |
| KR20220062038A (ko) * | 2019-09-13 | 2022-05-13 | 오리제니스 게엠베하 | 예를 들어 자가면역 질환의 치료를 위한 lrrk2, nuak1 및/또는 tyk2 키나제 조정제로서의 1,4-디히드로벤조[d]피라졸로[3,4-f][1,3]디아제핀 유도체 및 관련 화합물 |
-
2020
- 2020-09-11 KR KR1020227011532A patent/KR20220062038A/ko active Pending
- 2020-09-11 US US17/642,142 patent/US20220380374A1/en not_active Abandoned
- 2020-09-11 FI FIEP20788868.6T patent/FI4028017T3/fi active
- 2020-09-11 CN CN202080078998.0A patent/CN114793435B/zh active Active
- 2020-09-11 SI SI202030353T patent/SI4028017T1/sl unknown
- 2020-09-11 PT PT207888686T patent/PT4028017T/pt unknown
- 2020-09-11 EP EP23205855.2A patent/EP4327884A3/en active Pending
- 2020-09-11 PL PL20788868.6T patent/PL4028017T3/pl unknown
- 2020-09-11 EP EP20788868.6A patent/EP4028017B1/en active Active
- 2020-09-11 CN CN202411291626.2A patent/CN119775277A/zh active Pending
- 2020-09-11 AU AU2020344216A patent/AU2020344216A1/en not_active Abandoned
- 2020-09-11 JP JP2022516097A patent/JP7796007B2/ja active Active
- 2020-09-11 ES ES20788868T patent/ES2969088T3/es active Active
- 2020-09-11 DK DK20788868.6T patent/DK4028017T3/da active
- 2020-09-11 RS RS20240045A patent/RS65045B1/sr unknown
- 2020-09-11 HU HUE20788868A patent/HUE065093T2/hu unknown
- 2020-09-11 WO PCT/IB2020/000730 patent/WO2021048620A1/en not_active Ceased
- 2020-09-11 CA CA3154123A patent/CA3154123A1/en active Pending
-
2022
- 2022-03-13 IL IL291335A patent/IL291335A/en unknown
-
2025
- 2025-02-26 JP JP2025028912A patent/JP2025081660A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3154123A1 (en) | 2021-03-18 |
| CN114793435A (zh) | 2022-07-26 |
| JP2022548246A (ja) | 2022-11-17 |
| RS65045B1 (sr) | 2024-02-29 |
| WO2021048620A1 (en) | 2021-03-18 |
| EP4327884A3 (en) | 2024-05-01 |
| DK4028017T3 (da) | 2024-01-15 |
| AU2020344216A1 (en) | 2022-03-31 |
| FI4028017T3 (fi) | 2024-01-11 |
| KR20220062038A (ko) | 2022-05-13 |
| CN119775277A (zh) | 2025-04-08 |
| US20220380374A1 (en) | 2022-12-01 |
| PT4028017T (pt) | 2024-01-16 |
| SI4028017T1 (sl) | 2024-04-30 |
| EP4327884A2 (en) | 2024-02-28 |
| JP2025081660A (ja) | 2025-05-27 |
| CN114793435B (zh) | 2024-10-01 |
| EP4028017B1 (en) | 2023-12-06 |
| JP7796007B2 (ja) | 2026-01-08 |
| IL291335A (en) | 2022-05-01 |
| ES2969088T3 (es) | 2024-05-16 |
| EP4028017A1 (en) | 2022-07-20 |
| HUE065093T2 (hu) | 2024-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291338A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| IL291335A (en) | 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| PH12019502365A1 (en) | New bicyclic pyrazole derivatives | |
| WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| EP3500575C0 (en) | CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE, ITS PREPARATION AND USES | |
| DK3697784T5 (da) | Imidazo[4,5-b]pyridinforbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske forstyrrelser | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| HK1247203A1 (zh) | 取代的咪唑并[1，2-α]吡啶-2-基胺化合物及其药物组合物和使用方法 | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| SG11201907095UA (en) | DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | |
| EP3604306A4 (en) | MACROCYCLICAL DERIVATIVE OF PYRAZOL [3,4-D] PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND ASSOCIATED USE | |
| AU2017261291A1 (en) | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | |
| DK3658140T3 (da) | Kombinationer af aprocitentan med yderligere aktive bestanddele til behandlingen af resistent hypertension | |
| DK3873884T3 (da) | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme | |
| MX394784B (es) | Composiciones farmacéuticas de un inhibidor de tirosina cinasa de bruton. | |
| IL281924A (en) | New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making | |
| HK1206726A1 (en) | Imidazotriazinone compounds | |
| BR112018072168A2 (pt) | compostos derivados da pirimidina como inibidores da quinase jak | |
| MX2018002916A (es) | Metodos, composiciones y usos de nuevos inhibidores de fyn quinasa. | |
| EP4427815A3 (en) | Deuterium-enriched pirfenidone and methods of use thereof | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| DK3509598T3 (da) | Ny anvendelse af triazolo(4,5-d)pyrimidinderivater til forebyggelse og behandling af bakteriel infektion | |
| DOP2019000169A (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1 | |
| TN2018000321A1 (en) | 1,5-dihydr0-4h-pyrazol0[3,4-d]pyrimidin-4-0nes and 1,5-dihydr0-4h-pyrazol0[4,3-c]pyridin-4-0nes as pde1 inhibitors. |